Viela Bio, Inc. Common Stock (VIE)

Data is currently not available

Quotes

NEWS & ANALYSIS

VIE VIE PRESS RELEASES

VIE Press Releases

Published
Nov 10, 2020

Viela Bio Reports Third Quarter 2020 Financial Results and Program Highlights

Published
Nov 10, 2020
Published
Nov 5, 2020

Viela Bio Announces Final Results from Phase 1b Trial of VIB7734 in Patients with Cutaneous Lupus Erythematosus

Published
Nov 5, 2020
Published
Nov 2, 2020

Viela Bio to Webcast Third Quarter 2020 Financial Results and Program Highlights on November 10, 2020

Published
Nov 2, 2020
Published
Sep 3, 2020

Viela Bio Announces Data Presentations at the 8th Joint ACTRIMS-ECTRIMS Meeting, MS Virtual 2020

Published
Sep 3, 2020
Published
Aug 12, 2020

Viela Bio Reports Second Quarter 2020 Financial Results and Program Highlights

Published
Aug 12, 2020
Published
Aug 5, 2020

Viela Bio to Webcast Second Quarter 2020 Financial Results and Program Highlights on August 12, 2020

Published
Aug 5, 2020
Published
Jun 11, 2020

Viela Bio Announces U.S. FDA Approval of UPLIZNA™ (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)

Published
Jun 11, 2020
Published
May 27, 2020

Viela Bio Announces Pricing of Public Offering of Common Stock

Published
May 27, 2020
Published
May 26, 2020

Viela Bio Announces Proposed Public Offering of Common Stock

Published
May 26, 2020
Published
May 13, 2020

Viela Bio Reports First Quarter 2020 Financial Results and Program Highlights

Published
May 13, 2020
Published
May 13, 2020

Viela Bio Announces Positive Interim Results from a Phase 1b Study of VIB7734 in Patients with Cutaneous Lupus Erythematosus

Published
May 13, 2020
Published
May 6, 2020

Viela Bio to Webcast First Quarter 2020 Financial Results and Program Highlights on May 13, 2020

Published
May 6, 2020
Published
Apr 30, 2020

Viela Bio Announces Election of Rachelle Jacques to its Board of Directors

Published
Apr 30, 2020
Published
Mar 25, 2020

Viela Bio Reports Fourth Quarter and Full Year 2019 Financial Results and Business Highlights

Published
Mar 25, 2020
Published
Mar 18, 2020

Viela Bio to Webcast Fourth Quarter and Full Year 2019 Operating and Financial Results on March 25, 2020

Published
Mar 18, 2020
Published
Dec 11, 2019

Viela Bio Announces Initiation of Phase 2b Trial of VIB4920 in Sjögren’s Syndrome

Published
Dec 11, 2019
Published
Nov 14, 2019

Viela Bio Reports Third Quarter 2019 Financial Results and Business Highlights

Published
Nov 14, 2019
Published
Oct 9, 2019

Viela Bio Enters Strategic Collaboration with Mitsubishi Tanabe Pharma to Develop and Commercialize Inebilizumab for Autoimmune Diseases in Japan and Other Asia Regions

Published
Oct 9, 2019
Published
Oct 7, 2019

Viela Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Published
Oct 7, 2019
Published
Oct 2, 2019

Viela Bio Announces Pricing of Initial Public Offering

Published
Oct 2, 2019
Back to VIE Overview

Related Symbols

AMZN

Data is currently not available
AAPL

Data is currently not available
TSLA

Data is currently not available
INTC

Data is currently not available